Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir (Insulin Detemir [rDNA Origin] Injection).
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Insulin detemir (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PREDICTIVE-303
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 30 Jan 2016 Results (post-hoc sub-analysis) published in the Drugs and Aging (n = 2812).
- 07 Jul 2009 Actual number of patients (5652) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History